UNDERWRITING AGREEMENT between VIRPAX PHARMACEUTICALS, INC. and THINKEQUITY as Representative of the Several Underwriters VIRPAX PHARMACEUTICALS, INC.Underwriting Agreement • September 9th, 2021 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
The undersigned, Virpax Pharmaceuticals, Inc., a corporation formed under the laws of the State of Delaware (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
Agreement for the Rendering of Research ServicesAgreement • September 9th, 2021 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT for the rendering of research services (the “Agreement”) is entered into as of June 29, 2021 (the “Effective Date”) by and between LipocureRX, Ltd., a company organized and existing under the laws of Israel (“Lipocure”), and Virpax Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
Agreement for the Rendering of Research ServicesAgreement • September 9th, 2021 • Virpax Pharmaceuticals, Inc. • Pharmaceutical preparations • London
THIS AGREEMENT for the rendering of research services (the “Agreement”) is entered into as of June 30, 2021 (the "Effective Date") by and between Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) with offices at Hi-Tech Park, Edmond J. Safra Campus, Givat Ram, P.O.B 39135, Jerusalem 91390, Israel and Virpax Pharmaceuticals, Inc. (the “Company”) with offices at 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312 USA.
